Show simple item record

 

A plain language summary of the molecular changes in the tumors of people with BRAF V600E–mutant colorectal cancer in the BEACON study

dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMurphy, Danielle A.
dc.contributor.authorPu, Jie
dc.contributor.authorKopetz, Scott
dc.contributor.authorCiardiello, Fortunato
dc.contributor.authorDesai, Jayesh
dc.contributor.authorVan Cutsem, Eric
dc.contributor.authorTabernero, Josep
dc.date.accessioned2025-07-08T10:52:11Z
dc.date.available2025-07-08T10:52:11Z
dc.date.issued2025
dc.identifier.citationKopetz S, Danielle A. M, Jie P, Fortunato C, Jayesh D, Van Custem E, et al. A plain language summary of the molecular changes in the tumors of people with BRAF V600E–mutant colorectal cancer in the BEACON study. Futur Oncol. 2025;21(14):1713-23.
dc.identifier.issn1744-8301
dc.identifier.urihttp://hdl.handle.net/11351/13370
dc.descriptionColorectal cancer; Mutation
dc.description.abstractWhat is this summary about? This summary discusses the genetic and molecular changes in tumors of participants with BRAF V600E–mutant metastatic colorectal cancer who were treated with encorafenib plus cetuximab, with or without binimetinib, in the BEACON study. What were the results? Encorafenib plus cetuximab, with or without binimetinib, reduced the risk of participants dying compared with cetuximab plus chemotherapy, regardless of genetic or molecular colorectal cancer subtypes. The study also found genetic and molecular changes in the participants’ tumors during treatment that were associated with how long they lived. What do the results of the study mean? The types of genetic and molecular changes that occur during treatment in participants’ tumors can affect their response to treatment with BRAF and MEK inhibitors.
dc.language.isoeng
dc.publisherTaylor & Francis
dc.relation.ispartofseriesFuture Oncology;21(14)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectAnomalies cromosòmiques
dc.subjectRecte - Càncer - Tractament
dc.subjectCòlon - Càncer - Tractament
dc.subject.meshColorectal Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshMutation
dc.titleA plain language summary of the molecular changes in the tumors of people with BRAF V600E–mutant colorectal cancer in the BEACON study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1080/14796694.2025.2498880
dc.subject.decsneoplasias colorrectales
dc.subject.decs/farmacoterapia
dc.subject.decsmutación
dc.relation.publishversionhttps://doi.org/10.1080/14796694.2025.2498880
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Kopetz S] University of Texas MD Anderson Cancer Center, Houston, TX, USA. [Murphy DA] Formerly Pfizer, La Jolla, CA, USA. [Pu J] Formerly Pfizer, New York, NY, USA. [Ciardiello F] University of Campania Luigi Vanvitelli, Naples, Italy. [Desai J] Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. [Van Cutsem E] University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium. [Tabernero J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. University of Vic – Central University of Catalonia, Vic, Spain
dc.identifier.pmid40340632
dc.identifier.wos001484840400001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Name:
a-plain-language-summary-molec ...
Size:
2.485Mb
Format:
PDF
Description:
A plain language summary of the ...
View

This item appears in the following Collection(s)

Show simple item record